249 related articles for article (PubMed ID: 19595305)
1. Ras signaling and therapies.
Young A; Lyons J; Miller AL; Phan VT; Alarcón IR; McCormick F
Adv Cancer Res; 2009; 102():1-17. PubMed ID: 19595305
[TBL] [Abstract][Full Text] [Related]
2. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
3. Cancer targets in the Ras pathway.
Rodriguez-Viciana P; Tetsu O; Oda K; Okada J; Rauen K; McCormick F
Cold Spring Harb Symp Quant Biol; 2005; 70():461-7. PubMed ID: 16869784
[TBL] [Abstract][Full Text] [Related]
4. Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment?
Shinohara N; Koyanagi T
Urol Res; 2002 Oct; 30(5):273-81. PubMed ID: 12389114
[TBL] [Abstract][Full Text] [Related]
5. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Aoki Y; Niihori T; Narumi Y; Kure S; Matsubara Y
Hum Mutat; 2008 Aug; 29(8):992-1006. PubMed ID: 18470943
[TBL] [Abstract][Full Text] [Related]
6. A conserved RAS/mitogen-activated protein kinase pathway regulates DNA damage-induced cell death postirradiation in Radelegans.
Weidhaas JB; Eisenmann DM; Holub JM; Nallur SV
Cancer Res; 2006 Nov; 66(21):10434-8. PubMed ID: 17079464
[TBL] [Abstract][Full Text] [Related]
7. The impact of the regulatory design on the response of epidermal growth factor receptor-mediated signal transduction towards oncogenic mutations.
Wolf J; Dronov S; Tobin F; Goryanin I
FEBS J; 2007 Nov; 274(21):5505-17. PubMed ID: 17916191
[TBL] [Abstract][Full Text] [Related]
8. Deregulated Ras signaling in developmental disorders: new tricks for an old dog.
Schubbert S; Bollag G; Shannon K
Curr Opin Genet Dev; 2007 Feb; 17(1):15-22. PubMed ID: 17208427
[TBL] [Abstract][Full Text] [Related]
9. Small GTPase Ras and Rho expression in rat osteoblasts during spaceflight.
Kumei Y; Shimokawa H; Ohya K; Katano H; Akiyama H; Hirano M; Morita S
Ann N Y Acad Sci; 2007 Jan; 1095():292-9. PubMed ID: 17404041
[TBL] [Abstract][Full Text] [Related]
10. From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design.
Ramírez de Molina A; Rodríguez-González A; Lacal JC
Cancer Lett; 2004 Apr; 206(2):137-48. PubMed ID: 15013519
[TBL] [Abstract][Full Text] [Related]
11. Yeast screens for inhibitors of Ras-Raf interaction and characterization of MCP inhibitors of Ras-Raf interaction.
Khazak V; Kato-Stankiewicz J; Tamanoi F; Golemis EA
Methods Enzymol; 2006; 407():612-29. PubMed ID: 16757356
[TBL] [Abstract][Full Text] [Related]
12. KSR and CNK: two scaffolds regulating RAS-mediated RAF activation.
Clapéron A; Therrien M
Oncogene; 2007 May; 26(22):3143-58. PubMed ID: 17496912
[TBL] [Abstract][Full Text] [Related]
13. Ras up-regulation of cyclooxygenase-2.
Backlund MG; Mann JR; Wang D; Dubois RN
Methods Enzymol; 2006; 407():401-10. PubMed ID: 16757341
[TBL] [Abstract][Full Text] [Related]
14. [Molecular genetic diagnostics in syndromes associated with the RAS/MAPK signalling pathway].
Molven A; Søvik O; von der Lippe C; Steine SJ; Njølstad PR; Houge G; Prescott TE
Tidsskr Nor Laegeforen; 2009 Nov; 129(22):2358-61. PubMed ID: 19935936
[TBL] [Abstract][Full Text] [Related]
15. Using cells devoid of RAS proteins as tools for drug discovery.
Urosevic J; Sum EY; Moneo V; Drosten M; Dhawahir A; Becerra M; Carnero A; Barbacid M
Mol Carcinog; 2009 Nov; 48(11):1038-47. PubMed ID: 19526460
[TBL] [Abstract][Full Text] [Related]
16. RAS: target for cancer therapy.
Saxena N; Lahiri SS; Hambarde S; Tripathi RP
Cancer Invest; 2008 Nov; 26(9):948-55. PubMed ID: 18798058
[TBL] [Abstract][Full Text] [Related]
17. [Progress in the study of antitumor drug targeting on the Ras signaling pathway].
Zhu YJ; Jiang FC
Yao Xue Xue Bao; 2009 Jan; 44(1):1-10. PubMed ID: 19350814
[TBL] [Abstract][Full Text] [Related]
18. Prospective of Ras signaling in stem cells.
Chakrabarty K; Heumann R
Biol Chem; 2008 Jul; 389(7):791-8. PubMed ID: 18627319
[TBL] [Abstract][Full Text] [Related]
19. Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis.
Cakir M; Grossman AB
Expert Opin Ther Targets; 2009 Sep; 13(9):1121-34. PubMed ID: 19637976
[TBL] [Abstract][Full Text] [Related]
20. Interactions of Ras proteins with the plasma membrane and their roles in signaling.
Eisenberg S; Henis YI
Cell Signal; 2008 Jan; 20(1):31-9. PubMed ID: 17888630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
